This study reported outcomes of 15 patients with T1-2N0 glottic cancer treated to a total dose 70 Gy. The one- and two-year OS and metastases-free survival were 100%. One patient developed local failure and received salvage laryngectomy. The mean number of CTCAE grade I and II overall toxicity events per patient was 4.1. No higher-grade acute or late toxicity was reported. The authors concluded that PT for T1-2N0 glottic cancer resulted in exceptional treatment tolerability with high rates of laryngeal function preservation and promising oncological outcome. IMPT has the potential to become a standard treatment option for patients with early-stage laryngeal cancer.